A framework for quantifying the influence of adherence and dose individualization

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 4, 2016, Pages 452-459

  Assawasuwannakit, P ^a,b   Braund, R ^a   Duffull, S B ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; OMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR;

A PRIORI FORGIVENESS; ARTICLE; COMPARTMENT MODEL; DOSE INDIVIDUALIZATION; DRUG DOSE; HUMAN; INDIVIDUALIZATION; MEDICATION COMPLIANCE; PHARMACODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; TREATMENT RESPONSE; COMPUTER SIMULATION; DOSE CALCULATION; DRUG ADMINISTRATION; STATISTICAL MODEL; TREATMENT OUTCOME;

ATORVASTATIN CALCIUM; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEDICATION ADHERENCE; MODELS, STATISTICAL; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84960438326     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.268     Document Type: Article

References (30)

1. Vrijens, B., &, Urquhart, J., Patient adherence to prescribed antimicrobial drug dosing regimens. J. Antimicrob. Chemother. 55, 616-627 (2005).
2. Parienti, J.J., et al,. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob. Agents Chemother. 57, 2265-2271 (2013).
3. Vrijens, B., Claeys, M.J., Legrand, V., Vandendriessche, E., &, Van de Werf, F., Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). Br. J. Clin. Pharmacol. 77, 746-755 (2014).
4. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348, 633-638 (1996).
5. Rose, A.J., Ozonoff, A., Berlowitz, D.R., Henault, L.E., &, Hylek, E.M., Warfarin dose management affects INR control. J. Thromb. Haemost. 7, 94-101 (2009).
6. McDonald, H.P., Garg, A.X., &, Haynes, R.B., Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288, 2868-2879 (2002).
7. Kripalani, S., Yao, X., &, Haynes RB,. Interventions to enhance medication adherence in chronic medical conditions: A systematic review. Arch. Intern. Med. 167, 540-550 (2007).
8. Demonceau, J., et al,. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: A systematic literature review and meta-Analysis. Drugs 73, 545-562 (2013).
9. Nieuwlaat, R., et al,. Interventions for enhancing medication adherence. Cochrane Database Syst. Rev. 11, CD000011 (2014).
10. Urquhart, J., The electronic medication event monitor. Lessons for pharmacotherapy. Clin. Pharmacokinet. 32, 345-356 (1997).
11. Urquhart, J., Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv. Drug Deliv. Rev. 33, 207-219 (1998).
12. Boissel, J.P., &, Nony, P., Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance. Clin. Pharmacokinet. 41, 1-6 (2002).
13. Hughes, D.A., &, Walley, T., Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. Clin. Pharmacol. Ther. 74, 1-8 (2003).
14. Dickinson, L., et al,. Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing. J. Antimicrob. Chemother. 62, 161-167 (2008).
15. Osterberg, L.G., Urquhart, J., &, Blaschke, T.F., Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin. Pharmacol. Ther. 88, 457-459 (2010).
16. Lowy, A., et al,. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int. J. Clin. Pract. 65, 41-53 (2011).
17. Assawasuwannakit, P., Braund, R., &, Duffull, S.B., Quantification of the forgiveness of drugs to imperfect adherence. CPT Pharmacometrics Syst. Pharmacol. 4, e00004 (2015).
18. Andrews, T.C., Ballantyne, C.M., Hsia, J.A., &, Kramer, J.H., Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am. J. Med. 111, 185-191 (2001).
19. Blaschke, T.F., Osterberg, L., Vrijens, B., &, Urquhart, J., Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52, 275-301 (2012).
20. Stone, N.J., et al,. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63 (25 Pt B), 2889-2934 (2014).
21. Witt, D.M., Sadler, M.A., Shanahan, R.L., Mazzoli, G., &, Tillman, D.J., Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 127, 1515-1522 (2005).
22. Poli, D., Antonucci, E., Testa, S., Tosetto, A., Ageno, W., &, Palareti, G., Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 124, 824-829 (2011).
23. Wieloch, M., Själander, A., Frykman, V., Rosenqvist, M., Eriksson, N., &, Svensson, P.J., Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur. Heart J. 32, 2282-2289 (2011).
24. Narwal, R., Akhlaghi, F., Asberg, A., Hermann, M., &, Rosenbaum, S.E., Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite. Clin. Pharmacokinet. 49, 693-702 (2010).
25. Kim, J., et al,. A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin. Pharmacol. Toxicol. 109, 156-163 (2011).
26. Jacobsen, W., et al,. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 28, 1369-1378 (2000).
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
28. McTaggart, F., et al,. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am. J. Cardiol. 87, 28B-32B (2001).
29. Puchalski, T.A., Krzyzanski, W., Blum, R.A., &, Jusko, W.J., Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. J. Clin. Pharmacol. 41, 251-258 (2001).
30. Shin, J.M., &, Sachs, G., Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology 123, 1588-1597 (2002).